116 related articles for article (PubMed ID: 38662542)
1. The MYCN 5' UTR as a therapeutic target in neuroblastoma.
Volegova MP; Brown LE; Banerjee U; Dries R; Sharma B; Kennedy A; Porco JA; George RE
Cell Rep; 2024 May; 43(5):114134. PubMed ID: 38662542
[TBL] [Abstract][Full Text] [Related]
2. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
3. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
4. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
5. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
Rust A; Shah S; Hautbergue GM; Davletov B
Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29954071
[TBL] [Abstract][Full Text] [Related]
6.
Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
[No Abstract] [Full Text] [Related]
7. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
8. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
9. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
10. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.
Modelska A; Turro E; Russell R; Beaton J; Sbarrato T; Spriggs K; Miller J; Gräf S; Provenzano E; Blows F; Pharoah P; Caldas C; Le Quesne J
Cell Death Dis; 2015 Jan; 6(1):e1603. PubMed ID: 25611378
[TBL] [Abstract][Full Text] [Related]
11. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
Zhang H; Liu T; Yi S; Gu L; Zhou M
Mol Oncol; 2015 Aug; 9(7):1301-11. PubMed ID: 25864587
[TBL] [Abstract][Full Text] [Related]
12. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
13. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract][Full Text] [Related]
14. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
15. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
Ando K; Suenaga Y; Kamijo T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
17. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
18. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
[TBL] [Abstract][Full Text] [Related]
19. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]